Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2318]

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Subcutaneous versus intravenous daratumumab administration in patients with...

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

$Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )$

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival...

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Ribociclib and endocrine therapy improves survival for pre-menopausal women...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Latest in ovarian cancer treatment

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Latest in ovarian cancer treatment ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia...

Prof Hervé Dombret, University Paris Diderot, Paris, France

Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Prof Hervé Dombret, University Paris Diderot, Paris, France )

Master pathways and targets in T cell acute lymphoblastic leukaemia

Prof Jean Soulier - Hôpital Saint Louis, Paris, France

Master pathways and targets in T cell acute lymphoblastic leukaemia ( Prof Jean Soulier - Hôpital Saint Louis, Paris, France )

Second-line and beyond in mCRC: Optimising the benefit and reducing the risk

Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA

Second-line and beyond in mCRC: Optimising the benefit and reducing the risk ( Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA )

Beyond second-line therapy: New hope for mCRC patients in Egypt

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Beyond second-line therapy: New hope for mCRC patients in Egypt ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Multi-target kinase inhibitors: From data to practice

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Multi-target kinase inhibitors: From data to practice ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Advanced HCC: New systemic treatment options

Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt

Advanced HCC: New systemic treatment options ( Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt )

First- and second-line treatments for locally advanced renal cell carcinoma

Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA

First- and second-line treatments for locally advanced renal cell carcinoma ( Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA )

More from ecancer